<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
      <Volume-Issue>Volume 12, Issue 3</Volume-Issue>
      <Season>July-September, 2020</Season>
      <ArticleTitle>Nasal mucoadhesive thermoreversible in situ gel of phenytoin sodium for epilepsy</ArticleTitle>
          <FirstName>Sandeep K.</FirstName>
          <FirstName>Koshy M.</FirstName>
      <Abstract>Introduction: The aim of the present study was to formulate and characterize nasal mucoadhesive thermoreversible in situ gel of phenytoin sodium for the treatment of Epilepsy. Procedure: The in situ gel was prepared by cold method using thermoreversible polymer Pluronic F127, polyethylene glycol 4000, and propylene glycol which would enhance nasal residence time, absorption of drug across nasal-mucosal membrane, improve bioavailability, and dose reduction. The in situ gel was characterized in terms of gelation temperature, gelation time, pH, viscosity, drug content, mucoadhesive strength, and percentage cumulative release. Results: The gelation temperature and gelation time of the various formulations were found to be in the range of 28–38__degreesignC and 90–164 s, respectively. The pH was found to be in the range of 5.9–6.8. Mucoadhesive strength of various formulations was found to be between 47.032 and 126.775 g. The cumulative percentage release of phenytoin sodium from various formulations was found to be in the range of 39.2–53.2%. Conclusion: The formulated phenytoin sodium in situ gel is an ideal vehicle for specific treatment of epilepsy. Sustained and prolonged release of the drug, good stability, and biocompatibility characteristics make the in situ gel dosage forms reliable.</Abstract>
      <Keywords>Cold method, in situ gel, phenytoin sodium, pluronic F127</Keywords>
        <Abstract>https://isfcppharmaspire.com/ubijournal-v1copy/journals/abstract.php?article_id=13817&amp;title=Nasal mucoadhesive thermoreversible in situ gel of phenytoin sodium for epilepsy</Abstract>
        <References>1. Behl CR, Pimplaskar HK, Sileno AP, Demeireles J, Romeo VD. Effects of physiochemical properties and other factors on systemic nasal drug delivery. Adv Drug Deliv Rev 1998;29:89-116.&#13;
2. Gonjari ID, Kasture PV, Karmarkar AB. Solid In situ gelling nasal formulations: A tool for systemic drug delivery. AAPS Pharmscitech 2000;4:281-95.&#13;
3. Jagdale S, Shewale N, Kuchekar BS. Optimization of thermoreversible in situ nasal gel of timolol maleate. Scientifica 2016;2016:6401267.&#13;
4. Wang Y, Jiang S, Wang H, Bie H. A mucoadhesive, thermoreversible in situ nasal gel of geniposide for neurodegenerative diseases. PLoS One 2017;12:e0189478.&#13;
5. Taylor MJ, Tomlins P, Sahota TS. Thermoresponsive gels. Gels 2017;3:4.&#13;
6. Madan M, Bajaj A, Lewis S, Udupa N, Baig JA. In situ forming polymeric drug delivery systems. Indian J Pharm Sci 2009;71:242.&#13;
7. Wadell C, Bjork E, Camber O. Nasal drug delivery-evaluation of an in vitro model using Porcine nasal mucosa. Eur J Pharm Sci 1999;7:197-206.&#13;
8. Available from: https://www.drugs.com/phenytoin.html. [Last accessed on 2020 Jan 29].&#13;
9. Majithiya RJ, Ghosh PK, Umrethia ML, Murthy RS. Thermoreversiblemucoadhesive gel for nasal delivery of sumatriptan. AAPS Pharmscitech 2006;7:E80-6.&#13;
10. Shinde JV, Mali KK, Dias RJ, Havaldar VD, Mahajan NS. In situ mucoadhesive nasal gels of metoclopramide hydrochloride: Preformulation and formulation studies. J Pharm Res 2008;1:88-96.&#13;
11. Gonjari I, Karmarkar A, Hosmani A, Dhabale P. Preparation and in vitro evaluation of nasal gel of tramadol hydrochloride. Asian J Pharm Sci 2008;3:155-62.</References>